Experimental therapeutics in prostate cancer: where are we now and where do we need to go

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2012,（3）
• 页码范围: 421-422
• 页数: 2页
• 语种: 英文
• DOI: 10.1038/aja.2012.36

摘要

The explosion of new therapeutics in metastatic castrate-resistant prostate cancer (mCRPC) is unprecedented,but much more work needs to be done before we are satisfied.Six phase Ⅲ trials with an overall survival impact have now been reported (Table 1).1-6 Four of these trials were exclusively or predominantly in the mCRPC post-docetaxel space (MDV3100,abiraterone, 223radium and cabazitaxel).The 223radium trial also uniquely offered therapy to patients who were unsuitable for or refused docetaxel.The sipuleucel-T trial focused on mCRPC patients who were asymptomatic or minimally symptomatic; most of these patients were chemotherapy naive.